buy pemigatinib put fight
messag today esmo congress report full dataset
registr trial evalu fgfr-inhibitor pemigatinib previous
treat cholangiocarcinoma updat data confirm strong activ seen last
year esmo demonstr superior data exist incom regimen
orr month mpf month mo confirm remain
track submit nda base data year-end given convict
approv dataset particularli given high unmet medic need
increas peak market share probabl success assumpt rais pt
reiter buy
full dataset cholangiocarcinoma confirm strong activ clean
safeti profil seen interim present esmo report full
dataset registr ph ii studi evalu
pemigatinib previous treat local advanc metastat cholangiocarcinoma
cancer bile duct among patient document fgf/fgfr statu cohort
patient fusions/ rearrang pemigatinib monotherapi
demonstr orr includ pr patient
patient patient well sd yield diseas control rate
dcr furthermor pemigatinib yield month mpf month mo
larg line interim data present last year esmo confer includ
orr dcr month mpf month mo addit pemigatinib
remain well toler common advers event hyperphosphatemia
grade line previou data
data superior exist incom regimen like support fda
approv view recal outcom among cholangiocarcinoma patient typic
poor given unspecif symptom often result patient diagnos later
diseas progress stage iv treatment option exist particularli
relaps set standard-of-car second line chemo demonstr
orr dcr month mpf month mo power
trial demonstr clinic meaning orr goal clear
lower bound confid interv base result think pemigatinib
well posit potenti fda-approv earli next year view pemigatinib
potenti first-in-class best-in-class potenti competitor fgfr-inhibitor
derazantinib bpmuf/arql demonstr inferior interim efficaci data
on-going registr ph ii studi earlier year orr dcr
increas po pt pemigatinib contribut given
data high liklihood approv opinion rais po
cholangiocarcinoma opportun increas peak market share
given guid timelin push expect launch date
addit increas po cholangiocarcinoma given
increas convict follow believ de-risk event model
peak world-wide pemigatinib sale cholangiocarcinoma opportun contribut
peak increas pt follow data disclosur pemigatinib
contribut valuat
next pemigatinib pivot ph trial evalu pemigatinib
cholangiocarcinoma on-going follow initiati june continu dose
cohort on-going trial bladder cancer expect complet recruit
year-end per management guidanc ph ii trial head-to-head vs soc
page analyst certif import disclosur
evalu pemigatinib monotherapi combin treatment bladder
cancer initi ph ii tumor-agnost trial open
maintain buy rate given convict sustain jakafi growth
approv indic addit upsid potenti ruxolitinib topic dermatolog
opportun includ atop dermat vitiligo frontlin gvhd opportun
itacitinib well pemigatinib potenti fgfr-posit bladder cancer addit
pipelin candid repres potenti upsid estim numer catalyst
next month
page analyst certif import disclosur
valu previous per share use probabl adjust free cash flow project
jakafi iclusig olumi itacitinib topic ruxolitinib rais pt
follow pemigatinib data present esmo led us rais peak market share
po use discount rate consist commerci
stage biotech compani coverag termin growth rate
 regulatori commerci setback
potenti emerg new competitor
lower product sale expect
risk intellectu properti risk manag execut
page analyst certif import disclosur
chang fair valu acquisition-rel conting
interest incom net
unreal gains-to-loss long-term invest
incom tax
balanc sheet statement flow
compani report guggenheim secur llc estim
page analyst certif import disclosur
